Helping Clients Accelerate Time-to-market while Minimizing Risk by Streamlining Process, Increasing Transparency and Enhancing Collaboration

SANTA MONICA, Calif.: Dr.Evidence, the preeminent AI-enabled landscape intelligence platform helping life sciences enterprises get their products to market and keep them there, today announced significant enhancements to further accelerate clients’ time-to-market for new drugs and indications and de-risk the possibility of missing critical precedent from the market to support a successful path to approval.

The Dr.Evidence platform incorporates the broadest global content set available to generate landscape intelligence – over 100 million documents including pharmaceutical labels, regulatory approval packages, clinical trials, published literature, congresses and more. With specialized workflows, and advanced sharing and monitoring capabilities, this gives teams the necessary 360-degree view of the landscape to effectively inform clinical development and regulatory submission strategy.

The upgraded platform now features:

- Expanded Regulatory Intelligence module incorporating FDA Guidance documents and Orange and Purple Book content
- Generative AI Chat capability for regulatory approval packages
- Literature Search module with Generative AI-powered summarization Label Intelligence module covering 8 major health authorities

Dr.Evidence will showcase these new capabilities at the RAPS Convergence Conference in Long Beach, September 17-19.

Rose Higgins, CEO of Dr.Evidence, commented, “With two decades of delivering fit-for-purpose technology solutions to the industry, Dr.Evidence has acquired unsurpassed domain expertise and leverages an 'augmented intelligence' approach to development, combining ‘human-in-the-loop’ and advanced AI capabilities to deliver accurate and precise results, leading clients to an accelerated and more confident path to market.”

The Dr.Evidence platform serves as the central source of truth for pharmaceutical and biotechnology companies of all sizes, increasing transparency, breaking down silos across departments and geographies, and enhancing collaboration to more rapidly align on strategic decisions and generate deliverables to advance products into market, such as global regulatory strategy documents, briefing books, meeting packages for health authorities, target product profiles, company core data sheets, and long-range plans.

For organizations with generics and biosimilars on the market, the Dr.Evidence platform delivers proactive monitoring and notification of changes in innovator drug labels, as well as Orange and Purple Book content, to support strategy and compliance.

For more information, visit Dr.Evidence at Booth #843 during the RAPS Convergence Conference.

About Dr.Evidence

Dr.Evidence is the preeminent AI-enabled landscape intelligence platform for life sciences, helping clients get their products to market and keep them there. With 20 years of delivering fit-for-purpose technology solutions to the industry, Dr.Evidence has acquired unsurpassed domain expertise. The platform offers the most expansive content set available -- pharmaceutical labels, regulatory approval packages, health authority guidance documents, clinical trials, published literature, congresses and more -- to identify and analyze prior precedent and competitive products in informing strategy. By driving dramatic efficiencies, transparency, and collaboration across departments and geographies with specialized workflows, Dr.Evidence helps clients generate the critical deliverables needed to accelerate time-to-market.

Fonte: Business Wire